SWOG clinical trial number
CTSU/NRG-LU005
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Open
Abbreviated Title
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Status Notes
Closed to Accrual as of 06/23/2022 to sites in the United States and Canada. Patient transfers involving US and Canadian sites must be completed by way of submitting a completed CTSU Patient Transfer Form via the Regulatory Submission Portal.
Study will remain open in Japan until it meets the targeted 45 Japanese patients.
Site staff must complete ePRO online training in Rave prior to the first patient enrollment. Additional information is available in Protocol Related Documents; to locate, use the Document Type filter and select Education and Promotion.
Study will remain open in Japan until it meets the targeted 45 Japanese patients.
Site staff must complete ePRO online training in Rave prior to the first patient enrollment. Additional information is available in Protocol Related Documents; to locate, use the Document Type filter and select Education and Promotion.
Research committees
Lung Cancer
Treatment
Atezolizumab
Other Clinical Trials
SWOG Clinical Trial Number
S2302
PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER
Research Committee(s)
Lung Cancer
Activated
03/06/2023
Accrual
95%
Open
Phase
SWOG Clinical Trial Number
A082002
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007
RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open